Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides

Serkan Yazıcı,1 Emel Bülbül Başkan,1 Ferah Budak,2 Barbaros Oral,2 Şaduman Balaban Adim,3 Züleyde Ceylan Kalin,1 Güven Özkaya,4 Kenan Aydoğan,1 Hayriye Sarıcaoğlu,1 and Şükrün Tunali1

1Uludag University School of Medicine, Department of Dermatology and Venereology, Bursa, Turkey
2Uludag University School of Medicine, Department of Immunology, Bursa, Turkey
3Uludag University School of Medicine, Department of Pathology, Bursa, Turkey
4Uludag University School of Medicine, Department of Biostatistics, Bursa, Turkey

Correspondence should be addressed to Serkan Yazıcı; serkanyazici@uludag.edu.tr

Received 22 June 2015; Revised 4 November 2015; Accepted 24 November 2015

Academic Editor: Takami Sato

We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study. All patients had peripheral blood flow cytometry as part of their first visit. TNMB and histopathological staging of the cases were retrospectively performed in accordance with International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) criteria at the time of flow cytometry sampling. To determine prognostic value of cell surface antigens, cases were divided into two groups as stable and progressive disease. 17 flow cytometric analyses of 17 parapsoriasis (PP) and 11 analyses of 11 benign erythrodermic patients were included as control groups. Fluorescent labeled monoclonal antibodies were used to detect cell surface antigens: T cells (CD3+, CD4+, CD8+, TCRαβ, TCRγδ, CD7+, CD4+CD7+, and CD7−), B cells (HLA-DR+, CD19+, and HLA-DR+ CD19+), NKT cells (CD3+CD16+CD56+), and NK cells (CD3−CD16+CD56−). The mean value of all cell surface antigens was not statistically significant between parapsoriasis and MF groups. Along with an increase in cases of MF stage statistically significant difference was found between the mean values of cell surface antigens. Flow cytometric analysis of peripheral blood cell surface antigens in patients with mycosis fungoides may contribute to predicting disease stage and progression.

1. Introduction

Mycosis fungoides is the most common variant of primary cutaneous T cell lymphomas. Most of MF patients first present with long-standing reactive inflammatory dermatoses such as PP en plaque so-called premycotic eruptions [1]. Flow cytometric analysis of the cell surface antigens, expressed by peripheral blood cells, is widely used in the diagnosis and also management of hematologic malignancies; however, it has not been used routinely in the evaluation of MF patients. The diagnosis of MF is still challenging with current histopathological and molecular techniques especially in early stages [2]. Neoplastic T cells frequently have an altered level of expression of various surface T cell markers compared with normal T cells. These differences are sufficient to distinguish normal T cells from neoplastic T cells in the same population [3]. Peripheral blood flow cytometry can detect aberrant T cell populations even when there is no lymphocytosis or elevated total white blood cell count. Detection of T cell abnormalities by flow cytometry is increasing in use as an effective and a sensitive method in MF patients [4]. The importance of peripheral blood flow cytometry studies is highlighted by the ISCL/EORTC recommendations for diagnosis that include one or more of the following phenotypical abnormalities demonstrated by flow cytometry including peripheral blood CD4+/CD8+ rate being above 10, abnormal expression of pan-T cell markers including CD2+, CD3+, CD4+ antigens, and CD7...
of the patients, cases were divided into two groups according to the course of the follow-up process, and histopathological staging of cases were performed to determine the prognostic value of flow cytometric analysis of 17 PP and 11 analyses of benign erythrodermic patients as control groups. Flow cytometric analyses of 17 PP and 11 analyses of 11 benign erythroderma patients were included as control groups for the study. The age of MF patients during sampling ranged from baseline without new tumors (T<sub>1</sub>) or 25% increase in skin disease from baseline or new tumors (T<sub>2</sub>) to 50% clearance in skin disease (T<sub>4</sub>). Stable disease is described as <25% increase in skin disease from baseline without new tumors (T<sub>3</sub>) in patients with T<sub>1</sub>, T<sub>2</sub>, or T<sub>4</sub> only skin disease. Progressive disease is described as ≥25% increase in skin disease from baseline or new tumors (T<sub>3</sub>) in patients with T<sub>1</sub>, T<sub>2</sub>, or T<sub>4</sub> only skin disease or loss of response: in those with complete or partial response, increase of skin score of greater than the sum of plus 50% baseline score [8]. The study was approved by the local ethical committee and conducted according to the principles of the Declaration of Helsinki.

2.2. Flow Cytometric Analysis. Peripheral blood specimens were collected in EDTA tubes. Blood samples were transported to the flow cytometry laboratory where the specimens were processed and analyzed within 24 hours of receipt. After incubation of whole peripheral blood with monoclonal antibodies for 15 minutes at room temperature in the dark, erythrocytes were lysed with NH4CL for 10 min, followed by two washing steps using phosphate buffered saline solution. The cells were then resuspended and fixed with 1% paraformaldehyde.

Four-color flow cytometry was performed using FACSCanto (BD Biosciences, USA). Four-color direct immunofluorescent staining was performed as described by the manufacturer, using a 7-tube panel (70 × 15 mm). 100 μL (10<sup>5</sup>) cells blood samples, containing EDTA, were transferred to tubes and the tubes were placed in the Lyse Wash Assistant (LWA) (BD Biosciences, USA). Fluorescent labeled monoclonal antibodies were used to detect cell surface antigens: T cells (CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, TCRαβ<sup>+</sup>, TCRγδ<sup>+</sup>, CD7<sup>+</sup>, CD4<sup>+</sup>CD7<sup>+</sup>, CD4<sup>+</sup>CD7<sup>+</sup>, and CD7<sup>+</sup>), B cells (HLA-DR<sup>+</sup>, CD19<sup>+</sup>, and HLA-DR<sup>+</sup>CD19<sup>+</sup>), NK cells (CD3<sup>+</sup>CD16<sup>+</sup>CD56<sup>+</sup>), and NK cells (CD3<sup>+</sup>CD16<sup>+</sup>CD56<sup>+</sup>). Fluorescein isothiocyanate (FITC), phycoerythrin (PE), Allophycocyanin (APC), and Peridinin-Chlorophyll-Protein-Complex (PerCP) labeled fluorescent monoclonal antibodies (Beckman Coulter, France) were used. Cells were collected and analyzed on a FACSComp (BD Biosciences, USA) using FACSDiva (BD Biosciences, USA). The tubes were aspirated until dry to maximize cell yield. Lymphocytes were identified in the standard manner based on CD45 expression and side angle light scatter.

2.3. Statistical Analysis. SPSS for Windows Version 20.0 (SPSS Inc, Chicago, Illinois, USA) software package program was used for the statistical analysis. Variables were represented with mean, standard deviation, median, and maximum-minimum values. Categorical values of the variables given to cross-tables and differences between the two groups were analyzed with Pearson’s chi-square and Fisher’s exact test. Median and mean values of binary groups compared with using Kruskal-Wallis and Mann-Whitney tests, and for more than two groups ANOVA test was used. ROC curve analysis was performed to determine the cut-off values between progressive and stable disease groups. P < 0.05 was considered to be significant.

3. Results

A total of 121 MF patients (70 M, 51 F) were included in the study. The age of MF patients during sampling ranged
finding may show that flow cytometry is not enough alone to differentiate mycosis fungoides from benign dermatoses and parapsoriasis. CD3⁺ CD16⁻ CD56⁻ cells may differentiate benign erythrodermic and MF patients assessed with two-sided t-test (P = 0.027) (Table 3). According to histopathological and clinical stage in cases of mycosis fungoides, statistically significant differences were found between the mean values of all cell surface antigens (Tables 4 and 5). While increasing stage of disease the number of CD3⁺, CD4⁺, TCRαβ⁺, CD4⁺ CD7⁺, CD4⁺ CD7⁻, and CD7¹ cells and CD4⁺/CD8⁺ cell percentage were significantly increased and the number of CD8⁺, CD7⁺, HLA-DR⁺, CD19⁺, HLA-DR⁺, CD19⁺, CD3⁺ CD16⁻, and CD56⁺ cells decreased significantly (Table 5). These findings may be useful in identifying advanced stage cases in patients with MF.

When MF patients were examined in two groups as stable and progressive, all cell surface antigen except CD4⁺ CD7⁻ cells may play a role in determining the progression. According to ROC curve analysis results, flow cytometric results suggestive of disease progression were as follows: mean CD3⁺ cell percentage >79.1; mean CD4⁺ cell percentage >49.2; mean CD8⁺ cell percentage ≤5.2; CD4⁺/CD8⁺ percentage >2.4; mean TCRαβ⁺ cell percentage >73.1; TCRαβ⁺ cell percentage ≤2.4; CD7⁺ cell percentage ≤48; CD4⁺ CD7⁻ cell percentage >47.8; CD4⁺ CD7⁻ cell percentage >9.4; CD7¹ cell percentage >3.4; HLA-DR⁺ cell percentage ≤23.1; CD19⁺ cell percentage ≤6; HLA-DR⁺ CD19⁺ cell percentage ≤5; CD3⁺ CD16⁻ CD56⁻ cell percentage ≤1; CD3⁺ CD16⁻ CD56⁻ cell percentage ≤9.9 in peripheral blood at any time (Table 6).

### 4. Discussion

The diagnosis of MF remains a challenging area in dermatopathology and conclusive diagnosis is often difficult, necessitating the terms "diagnostic of," "consistent with," and "suggestive of" to describe the disease and histopathologic finding needs to be confirmed with the immunohistochemical studies with some limitations in between [9]. The cluster of differentiation (termed as Cluster of Designation or Classification Determinant) (CD) is a protocol used for the identification and investigation of cell surface molecules for immunophenotyping of cells. The use of combining markers has allowed more specific definitions for cell types within the immune system than one molecule [10, 11]. Previous studies using flow cytometry to analyze skin biopsy specimens for the diagnosis of CTCL and MF have been performed and reported that flow cytometry is a highly sensitive and specific diagnostic test for MF [4, 12, 13]. In addition to skin biopsy specimens, flow cytometric analysis has proven to be an efficient and sensitive method to detect and enumerate MF/SS cells in the peripheral blood [3, 14, 15]. Depending on the degree of differentiation of neoplastic cells one or more altered expressions of T cell related antigens including CD2⁺, CD3⁺, CD4⁺, CD7⁺, or CD26⁺, were identified in 92% of cases as positive for malignant T cell clones, with loss of CD26⁺ being the most common (70%), and CD56⁻ cases have been reported [16, 17]. However, increased CD26⁺ cells, or CD7⁺ cells, and even altered expression levels of other more specific T cell markers, such as CD3⁺ and CD4⁺, were also observed in nonneoplastic samples. That loss or dim

---

**Table 2: Clinical and demographic features of MF patients and histopathological and TNM staging of cases according to the Bunn-Lambert staging system and ISCL/EORTC criteria.**

| n      | 121 |
|--------|-----|
| Gender |      |
| ♂/♀   | 51/70 |
| Age (y) | Mean ± SD | 54.42 ± 13.81 |
|        | Median; min.–max. | 54.0; 18–90 |
| Duration of disease (y) | Mean ± SD | 7.14 ± 5.60 |
|        | Median; min.–max. | 5.0; 1–35 |
| Follow-up period (y) | Mean ± SD | 4.28 ± 2.96 |
|        | Median; min.–max. | 4; 1–14 |
| Coursing | Stable | 105 |
|        | Progressive | 16 |
|        | Eksitus | 5 |
| Histopathological stage | Patch | 75 |
|        | Plaque | 37 |
|        | Tumor | 9 |
| Clinical (T) stage | T₁ | 33 |
|        | T₂ | 68 |
|        | T₃ | 7 |
|        | T₄ | 13 |
| Lymph node (N) involvement | None | 109 |
|        | Positive | 12 |
| TNM staging | Early (IA – IIA) |      |
|        | IA | 33 |
|        | IB | 67 |
|        | IIA | 1 |
| Late (IIB–IV) | IIB | 6 |
|        | III | 10 |
|        | IV | 4 |

from 18 to 89 years (mean ± SD: 54.42 ± 13.81). The age of 17 parapsoriasis patients (6 M, 11 F) ranged from 17 to 62 (mean ± SD: 46.99 ± 12.05). The age of benign erythroderma patients ranged from 36 to 83. MF patients were followed up for an average of 4.28 ± 2.96 years, 105 cases were accepted as stable, and 16 cases were progressive. Clinical and demographic features of MF patients and histopathological and TNM staging of cases according to the Bunn-Lambert staging system and ISCL/EORTC criteria were summarized in Table 2.
Table 3: The mean value of all cell surface antigens between groups.

| CD molecule | Mycosis fungoides | Parapsoriasis | Benign erythroderma |
|-------------|-------------------|---------------|---------------------|
| | \( n \): 121 | \( n \): 17 | \( n \): 11 |
| CD3\(^+\) | | | 0.917 |
| Mean ± SD | 73.66 ± 9.62 | 71.12 ± 3.33 | 62.97 ± 23.26 |
| Median; min.–max. | 73.60; 48.70–98.70 | 70.90; 67.70–74.70 | 58.70; 43.60–90.90 |
| CD4\(^+\) | | | 0.754 |
| Mean ± SD | 47.54 ± 13.26 | 43.0 ± 8.81 | 39.62 ± 27.09 |
| Median; min.–max. | 45.3 ± 15.30–97.50 | 48.70; 31.20–50.40 | 32.05; 15.80–78.60 |
| CD8\(^+\) | | | 0.954 |
| Mean ± SD | 23.49 ± 10.62 | 25.96 ± 4.86 | 20.95 ± 9.86 |
| Median; min.–max. | 22.0; 0.50–73.30 | 24.9; 21.40–32.60 | 20.3; 10.60–32.60 |
| CD4\(^+\) /CD8\(^+\) | | | 0.836 |
| Mean ± SD | 5.61 ± 18.69 | 1.74 ± 0.6 | 2.40 ± 2.09 |
| Median; min.–max. | 2.0; 0.2–183.2 | 2.0; 0.90–2.30 | 1.95; 0.60–5.10 |
| TCR\(\alpha\beta\) | | | 0.944 |
| Mean ± SD | 4.09 ± 2.91 | 3.10 ± 2.10 | 3.35 ± 4.43 |
| Median; min.–max. | 3.20; 0.10–13.60 | 4.30; 0.80–4.80 | 1.20; 1.0–10.0 |
| CD7\(^+\) | | | 0.585 |
| Mean ± SD | 74.22 ± 12.60 | 80.0 ± 3.77 | 77.4 ± 4.35 |
| Median; min.–max. | 76.60; 2.80–98.0 | 79.2; 74.60–84.0 | 79.05; 71.10–80.40 |
| CD4\(^+\) CD7\(^+\) | | | 0.478 |
| Mean ± SD | 38.98 ± 11.50 | 40.68 ± 7.40 | 37.22 ± 17.86 |
| Median; min.–max. | 38.60; 9.60–96.50 | 44.80; 31.0–46.80 | 31.75; 22.30–63.10 |
| CD4\(^+\) CD7\(^-\) | | | 0.193 |
| Mean ± SD | 9.62 ± 11.53 | 4.52 ± 1.43 | 4.95 ± 3.87 |
| Median; min.–max. | 5.60; 0.50–88.90 | 4.90; 2.20–6.10 | 3.40; 2.30–10.70 |
| CD71\(^+\) | | | 0.091 |
| Mean ± SD | 5.70 ± 9.98 | 1.80 ± 0.71 | 15.65 ± 23.69 |
| Median; min.–max. | 3.0; 0.1–71.0 | 1.90; 0.8–2.80 | 4.95; 1.6–51.1 |
| HLA-DR\(^+\) | | | 0.368 |
| Mean ± SD | 30.47 ± 10.05 | 28.06 ± 5.81 | 37.22 ± 16.46 |
| Median; min.–max. | 29.2; 2.20–60.20 | 26.4; 20.6–36.0 | 33.6; 21.80–59.90 |
| CD19\(^+\) | | | 0.468 |
| Mean ± SD | 11.66 ± 4.81 | 12.74 ± 4.77 | 9.40 ± 3.84 |
| Median; min.–max. | 11.70; 1.0–24.80 | 10.90; 8.90–20.80 | 9.95; 4.90–12.80 |
| HLA-DR\(^+\) CD19\(^+\) | | | 0.559 |
| Mean ± SD | 10.80 ± 4.80 | 12.22 ± 4.70 | 8.20 ± 3.34 |
| Median; min.–max. | 10.70; 0.30–24.70 | 10.40; 8.70–20.10 | 50; 4.60–11.20 |
| B cell surface antigens | | | |
| CD3\(^-\) CD16\(^+\) CD56\(^+\) | | | 0.027 |
| Mean ± SD | 3.31 ± 3.26 | 1.54 ± 0.78 | 1.92 ± 1.30 |
| Median; min.–max. | 2.20; 0.20–20.50 | 1.20; 0.90–2.80 | 1.95; 0.70–3.10 |
| CD3\(^-\) CD16\(^-\) CD56\(^+\) | | | 0.523 |
| Mean ± SD | 12.92 ± 8.06 | 13.56 ± 5.28 | 16.87 ± 1.83 |
| Median; min.–max. | 12.80; 0.10–39.80 | 13.60; 7.30–21.50 | 17.55; 2.20–30.20 |
Table 4: The mean value of all cell surface antigens according to histopathological stage.

| Histopathological stage | Patch | Plaque | Tumor | P value |
|-------------------------|-------|--------|-------|---------|
|                         | n     |        |       |         |
| T cells surface antigens|       |        |       |         |
| CD3⁺                   | 101   | 50     | 12    | 0.000† |
| Mean ± SD              | 71.26 ± 7.72 | 75.16 ± 9.12 | 88.90 ± 7.68 |  
| Median; min.–max.      | 71.50; 51.30–89.10 | 76.30; 48.70–92.20 | 88.80; 75.40–98.70 |
| CD4⁺                   | 44.56 ± 8.32  | 47.22 ± 12.03  | 77.76 ± 15.58 |
| Mean ± SD              | 44.50; 28.30–73.60 | 47.60; 20.60–66.20 | 79.60; 55.50–97.50 |
| Median; min.–max.      | 24.24 ± 9.32  | 25.99 ± 10.52  | 7.98 ± 8.56  |
| CD8⁺                   | 2.18 ± 1.16   | 2.89 ± 5.23    | 43.41 ± 55.33 |
| Mean ± SD              | 1.90; 0.20–35.30 | 1.80; 0.30–35.30 | 19.20; 2.50–183.20 |
| Median; min.–max.      | 66.63 ± 8.14   | 69.26 ± 8.22   | 86.39 ± 8.43  |
| CD4⁺/CD8⁺              | 6.38 ± 2.97   | 4.26 ± 2.75    | 12.8 ± 4.43   |
| Mean ± SD              | 3.60; 0.60–13.60 | 3.35; 0.50–11.20 | 1.20; 0.10–10.0 |
| Median; min.–max.      | 76.68 ± 10.28  | 71.99 ± 9.32   | 73.05 ± 27.14 |
| CD7⁺                   | 38.91 ± 8.48  | 35.89 ± 8.22   | 51.34 ± 27.20 |
| Mean ± SD              | 9.65; 13.40–54.50 | 35.3; 16.0–53.10 | 48.70; 9.60–96.50 |
| Median; min.–max.      | 7.68 ± 10.28  | 71.99 ± 9.32   | 73.05 ± 27.14 |
| CD4⁺ CD7⁺              | 10.79 ± 4.65  | 11.87 ± 4.36   | 6.80 ± 5.86   |
| Mean ± SD              | 5.0; 1.0–51.30 | 7.40; 2.20–35.90 | 20.80; 0.50–88.90 |
| Median; min.–max.      | 4.47 ± 7.77   | 3.94 ± 4.66    | 22.21 ± 21.28 |
| B cells surface antigens|       |        |       |         |
| HLA-DR⁺                | 31.10 ± 9.76  | 32.49 ± 7.39   | 17.69 ± 12.73 |
| Mean ± SD              | 28.45; 11.40–60.20 | 31.80; 18.80–50.40 | 16.30; 2.20–43.70 |
| Median; min.–max.      | 11.55 ± 4.74  | 12.84 ± 4.44   | 8.11 ± 5.29   |
| CD19⁺                  | 10.79 ± 4.65  | 11.87 ± 4.36   | 6.80 ± 5.86   |
| Mean ± SD              | 10.65; 1.20–24.70 | 11.95; 2.90–20.50 | 7.80; 0.30–15.50 |
| Median; min.–max.      | 2.10; 0.20–20.50 | 2.55; 0.50–12.30 | 0.90; 0.20–6.20 |
| NK cells surface antigens|       |        |       |         |
| CD3⁺ CD16⁺ CD56⁺       | 3.38 ± 3.46   | 3.61 ± 3.01    | 1.60 ± 1.86   |
| Mean ± SD              | 2.10; 0.20–20.50 | 2.55; 0.50–12.30 | 0.90; 0.20–6.20 |
| NK cells surface antigens|       |        |       |         |
| CD3⁺ CD16⁺ CD56⁺       | 14.82 ± 8.14  | 11.73 ± 6.30   | 2.20 ± 2.35   |
| Mean ± SD              | 14.40; 2.60–39.80 | 11.50; 2.10–35.80 | 1.50; 0.10–8.0 |
| Median; min.–max.      | 14.82 ± 8.14  | 11.73 ± 6.30   | 2.20 ± 2.35   |

†: decreasing with stage; †: increasing with stage.
Table 5: The mean values of all cell surface antigens according to clinical stage.

| Clinical (T) stage | $T_1$ | $T_2$ | $T_3$ | $T_4$ | $n$ | $P$ value |
|-------------------|-------|-------|-------|-------|-----|-----------|
|                   |       |       |       |       |     |           |
| $T_1$             |       |       |       |       |     |           |
| Mean ± SD         | 73.93 ± 7.07 | 71.31 ± 9.01 | 88.41 ± 8.67 | 77.25 ± 17.64 | 47 | 0.000† |
| Median; min.–max. | 74.50; 62.30–92.60 | 71.80; 48.70–96.50 | 87.70; 79.10–98.70 | 85.35; 43.60–93.20 |     |           |
| $T_2$             |       |       |       |       |     |           |
| Mean ± SD         | 44.63 ± 9.42 | 44.49 ± 8.60 | 75.18 ± 19.31 | 60.27 ± 24.06 | 95 | 0.000† |
| Median; min.–max. | 44.70; 15.50–66.20 | 44.70; 20.60–63.90 | 74.35; 55.50–97.50 | 65.20; 15.80–92.30 |     |           |
| $T_3$             |       |       |       |       |     |           |
| Mean ± SD         | 26.75 ± 10.56 | 24.12 ± 9.36 | 11.41 ± 10.32 | 14.23 ± 9.68 | 6 | 0.005† |
| Median; min.–max. | 23.20; 14.10–73.30 | 23.45; 9.40–66.30 | 11.60; 0.50–22.50 | 15.10; 1.50–32.60 |     |           |
| $T_4$             |       |       |       |       |     |           |
| Mean ± SD         | 2.7 ± 5.16 | 2.19 ± 1.21 | 51.10 ± 74.46 | 13.97 ± 20.21 | 16 | 0.000† |
| Median; min.–max. | 1.90; 0.20–35.30 | 1.80; 0.30–78.0 | 10.35; 2.50–183.20 | 3.90; 0.60–61.50 |     |           |
| T cells surface antigens |
| $CD3^+$           |       |       |       |       |     |           |
| Mean ± SD         | 44.63 ± 9.42 | 44.49 ± 8.60 | 75.18 ± 19.31 | 60.27 ± 24.06 | 95 | 0.000† |
| Median; min.–max. | 44.70; 15.30–66.20 | 44.70; 20.60–63.90 | 74.35; 55.50–97.50 | 65.20; 15.80–92.30 |     |           |
| $CD4^+$           |       |       |       |       |     |           |
| Mean ± SD         | 77.89 ± 6.33 | 74.19 ± 11.33 | 79.63 ± 15.65 | 71.68 ± 17.65 | 16 | 0.000† |
| Median; min.–max. | 78.20; 50.0–87.10 | 76.0; 45.80–86.0 | 86.3; 76.90–98.0 | 76.0; 42.0–93.70 |     |           |
| $CD8^+$           |       |       |       |       |     |           |
| Mean ± SD         | 3.31 ± 2.78 | 4.79 ± 8.39 | 14.36 ± 15.71 | 17.45 ± 21.59 | 2.50; 0.3–11.30 | 0.002† |
| Median; min.–max. | 11.70; 1.50–19.10 | 11.95; 3.20–24.80 | 6.80; 1.0–15.70 | 8.50; 2.30–18.10 | 8.67 | 0.002† |
| B cells surface antigens |
| $CD3^+$           |       |       |       |       |     |           |
| Mean ± SD         | 29.46 ± 8.79 | 32.37 ± 9.11 | 21.56 ± 15.76 | 28.15 ± 15.30 | 2.50; 0.3–11.30 | 0.001† |
| Median; min.–max. | 27.50; 19.60–56.40 | 31.10; 11.40–60.20 | 22.0; 3.80–43.70 | 25.60; 2.20–59.90 | 3.0; 0.10–71.0 | 0.002† |
| $CD19^+$          |       |       |       |       |     |           |
| Mean ± SD         | 11.37 ± 3.96 | 12.48 ± 4.89 | 8.13 ± 6.41 | 8.67 ± 4.37 | 10.53; 3.92 | 0.021† |
| Median; min.–max. | 11.70; 1.50–19.10 | 11.95; 3.20–24.80 | 6.80; 1.0–15.70 | 8.50; 2.30–18.10 | 11.20; 2.90–24.70 | 0.030† |
| $CD3^+$ $CD19^+$  |       |       |       |       |     |           |
| Mean ± SD         | 3.46 ± 3.10 | 3.57 ± 3.50 | 2.06 ± 2.12 | 1.50 ± 1.16 | 2.50; 0.3–11.30 | 0.006† |
| Median; min.–max. | 2.50; 0.3–16.60 | 2.25; 0.20–20.50 | 1.60; 0.20–6.20 | 1.25; 0.20–3.80 | 2.70; 0.10–8.0 | 0.000† |
| $CD4^+$           |       |       |       |       |     |           |
| Mean ± SD         | 13.28 ± 6.34 | 14.34 ± 8.30 | 2.90 ± 2.92 | 8.86 ± 9.84 | 13.10; 2.60 | 0.000† |
| Median; min.–max. | 13.60; 2.10–39.80 | 13.60; 2.10–39.80 | 2.70; 0.10–8.0 | 3.30; 0.10–30.20 | 4.75; 0.30–15.50 | 0.040† |

†: decreasing with stage; †: increasing with stage.
### Table 6: ROC curve analysis of the investigated cell surface antigens to predict the cut-off value.

| Cell surface antigen | Cut-off value criterion | Area under curve | P value | Sensitivity (95% CI) | Specificity (95% CI) |
|----------------------|-------------------------|------------------|--------|----------------------|----------------------|
| **T cells surface antigens** |             |                  |        |                      |                      |
| CD3$^+$         | $> 79.1$                | 0.859            | 0.001  | 87.50 (61.6–98.1)    | 84.56 (22.5–55.2)    |
| CD4$^+$         | $> 49.2$                | 0.880            | 0.001  | 87.50 (61.6–98.1)    | 84.56 (77.7–90.0)    |
| CD8$^+$         | $\leq 5.2$              | 0.835            | 0.001  | 62.5 (35.5–84.7)     | 98.66 (95.2–99.8)    |
| CD4$^+$/CD8$^+$ | $> 2.4$                 | 0.873            | 0.001  | 93.75 (69.7–99.0)    | 69.80 (61.0–77.0)    |
| TCR$\alpha\beta$| $> 73.1$                | 0.887            | 0.001  | 92.86 (66.1–98.8)    | 72.29 (71.6–85.7)    |
| CD4$^+$/CD8$^+$ | $\leq 2.4$              | 0.847            | 0.001  | 85.71 (57.2–97.8)    | 73.38 (65.2–80.5)    |
| CD7$^+$         | $\leq 48.0$             | 0.647            | 0.036  | 78.57 (49.2–95.1)    | 50.74 (42.0–59.4)    |
| CD4$^+$/CD7$^+$ | $> 47.8$                | 0.680            | 0.028  | 50 (23.1–76.9)       | 89.51 (83.3–94.0)    |
| CD4$^+$/CD7$^-$ | $> 9.4$                 | 0.660            | 0.053  | 64.29 (35.2–87.1)    | 82.27 (74.9–88.2)    |
| CD71$^+$        | $> 3.4$                 | 0.831            | 0.001  | 92.86 (66.1–98.8)    | 63.43 (54.7–71.6)    |
| **B cells surface antigens** |             |                  |        |                      |                      |
| HLA-DR$^+$      | $\leq 23.1$             | 0.734            | 0.001  | 56.25 (26.9–80.2)    | 97.3 (93.2–99.2)     |
| CD19$^+$        | $\leq 6$                | 0.691            | 0.001  | 43.75 (19.8–70.1)    | 89.86 (83.8–94.2)    |
| HLA-DR$^+$/CD19$^+$ | $\leq 5$                | 0.723            | 0.001  | 56.25 (29.9–80.2)    | 85.14 (78.4–90.4)    |
| **NKT cells surface antigens** |             |                  |        |                      |                      |
| CD3$^+$/CD16$^+$/CD56$^+$ | $\leq 1$ | 0.649            | 0.023  | 68.75 (41.4–88.9)    | 62.16 (53.8–70.0)    |
| **NK cells surface antigens** |             |                  |        |                      |                      |
| CD3$^+$/CD16$^+$/CD56$^+$ | $\leq 9.9$ | 0.869            | 0.001  | 75.0 (47.6–92.6)     | 92.52 (87.0–96.2)    |

expression of CD7 and CD26 can be found in patients with benign inflammatory dermatoses and aberrant dim CD3 can be observed in nonneoplastic T cells [4]. Flow cytometric studies of the peripheral blood may show expansion of the CD4$^+$/CD7$^+$ population reflective of circulating atypical lymphocytes of Sezary type [18]. Lymphoma cells in the peripheral blood, especially at high levels, have been recognized as an independent adverse prognostic indicator in patients with mycosis fungoides, and the International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of European Organization for Research and Treatment of Cancer revised the mycosis fungoides/Sezary syndrome staging criteria in 2007 to incorporate blood (B) involvement as a major prognostic factor and defined the criteria for B-staging. Natural Killer activity of peripheral blood mononuclear cells in patients with MF was investigated with controlled study and revealed that patients with advanced disease had a significant defect of Natural Killer activity [19]. T cell lymphomas with aberrant CD20 (B cell surface antigen) expression, associated with worse prognosis, have been reported [20–22]. Hristov et al. reported that changes in abnormal populations parallel changes in patient's clinical course and increasing numbers of abnormal T cells were associated with worsening disease, and authors suggested that flow cytometry provides valuable information for diagnosis, prognosis, and therapeutic efficacy in MF/SS [23].

To the best of our knowledge this is the largest study to assess the prognostic role and clinical utility of flow cytometry in patients with MF. Peripheral blood samples as a diagnostic and tool for MF. Although, in cases of plaque or tumoral stage of MF, immunophenotypical abnormalities are significant, the significance of flow cytometric analysis in early stage MF is limited. Our findings suggest that T cell phenotype affects the clinical behaviour of MF compatible with the previous reports.

### 5. Conclusion

We concluded that flow cytometric analysis of peripheral blood cell surface antigens in patients with mycosis fungoides may contribute to identifying an advanced stage and predicting the disease progression. Flow cytometry is less time consuming and is a prognostic tool for the management of MF.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

### References

[1] E. Olsen, E. Vonderheid, N. Pimpinelli et al., “Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer,” *Blood*, vol. 110, no. 6, pp. 1713–1722, 2007.

[2] H. J. Meyerson, “Flow cytometry for the diagnosis of mycosis fungoides,” *Giornale Italiano di Dermatologia e Venereologia*, vol. 143, no. 1, pp. 21–41, 2008.

[3] M. Lima, J. Almeida, M. dos Anjos Teixeira et al., “Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sezary’s syndrome,” *Haematologica*, vol. 88, no. 8, pp. 874–887, 2003.
[4] S. Oshtory, N. Apisarnthanarax, A. C. Gilliam, K. D. Cooper, and H. J. Meyerson, "Usefulness of flow cytometry in the diagnosis of mycosis fungoides," Journal of the American Academy of Dermatology, vol. 57, no. 3, pp. 454–462, 2007.

[5] E. Olsen, E. Vonderheid, N. Pimpinelli et al., "ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization for Research and Treatment of Cancer (EORTC)," Blood, vol. 110, no. 6, pp. 1713–1722, 2007.

[6] M.-L. Jullié, M. Carlotti, A. Vivot Jr. et al., "CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact," American Journal of Surgical Pathology, vol. 37, no. 12, pp. 1845–1854, 2013.

[7] A. E. S. Brooks, "Skin-resident CD4+ T cells express NK receptors: lessons from skin pathologies," Cytometry Part A, vol. 85, pp. 827–829, 2014.

[8] E. A. Olsen, S. Whittaker, Y. H. Kim et al., "Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer," Journal of Clinical Oncology, vol. 29, no. 18, pp. 2598–2607, 2011.

[9] R. T. Hoppe, G. S. Wood, and E. A. Abel, "Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment," Current Problems in Cancer, vol. 14, no. 6, pp. 295–371, 1990.

[10] J. K. C. Chan, C. S. Ng, and P. K. Hui, "A simple guide to the terminology and application of leucocyte monoclonal antibodies," Histopathology, vol. 12, no. 5, pp. 461–480, 1988.

[11] H. Zola, B. Swart, A. Banham et al., "CD molecules 2006—human cell differentiation molecules," Journal of Immunological Methods, vol. 319, no. 1-2, pp. 1–5, 2007.

[12] C. H. Jokinen, J. R. Fromm, Z. B. Argenyi, J. Olerud, B. L. Wood, and H. A. Greisman, "Flow cytometric evaluation of skin biopsies for mycosis fungoides," American Journal of Dermatopathology, vol. 33, no. 5, pp. 483–491, 2011.

[13] K. Kelemen, C. R. White, K. Gatter, R. M. Brazier, and G. Fan, "Immunophenotypic correlation between skin biopsy and peripheral blood findings in mycosis fungoides," American Journal of Clinical Pathology, vol. 134, no. 5, pp. 739–748, 2010.

[14] S. Hara, T. Yokote, T. Akioka et al., "Flow cytometric immunophenotyping of peripheral T cell neoplasms Using CD3 gating," Acta Haematologica, vol. 121, no. 1, pp. 11–18, 2009.

[15] B. Feng, J. L. Jorgensen, D. Jones et al., "Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging," Modern Pathology, vol. 23, no. 2, pp. 284–295, 2010.

[16] R. M. de Tute, "Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies," Histopathology, vol. 58, no. 1, pp. 90–105, 2011.

[17] L. C. Edsall and J. W. Patterson, "Cutaneous T-cell lymphoma: important diagnostic tools," Giornale Italiano di Dermatologia e Venerologia, vol. 145, no. 3, pp. 323–344, 2010.

[18] H. Wu, M. Smith, M. M. Millenson et al., "Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions," Journal of Investigative Dermatology, vol. 121, no. 6, pp. 1522–1530, 2003.

[19] S. Levy, J.-L. Tempé, P. Caussade et al., "Stage-related decrease in natural killer cell activity in untreated patients with mycosis fungoides," Cancer Immunology Immunotherapy, vol. 18, no. 2, pp. 138–140, 1984.

[20] N. N. Balmer, L. Hughely, K. J. Busam, V. Reddy, and A. A. Andea, "Primary cutaneous peripheral T-cell lymphoma with aberrant coexpression of CD20: case report and review of the literature," The American Journal of Dermatopathology, vol. 31, no. 2, pp. 187–192, 2009.

[21] A. Garcia-Herrera, L. Colomo, M. Camós et al., "Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome," Journal of Clinical Oncology, vol. 26, no. 20, pp. 3364–3371, 2008.

[22] G. Ferrara, C. Chiarelli, and S. Simonetti, "B-cell lymphofollicular infiltrates in mycosis fungoides," Tumori, vol. 96, no. 3, pp. 487–491, 2010.

[23] A. C. Hristov, E. C. Vonderheid, and M. J. Borowitz, "Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome," American Journal of Clinical Pathology, vol. 136, no. 6, pp. 944–953, 2011.